

Pharmacy Formulary Updates for April 2021

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status in April 2021:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Direct Formulary
Tykerb (brand)	NC; SP; QL (180/30)
Kuvan	NC; SP
Monurol (brand)	NC
Banzel susp 40mg/ml (brand)	NC; QL
Taytulla (Brand)	T3; PA; ACA
meclizine 50mg (generic)	NC
Jynarque	Tier 3
Riabni	MB; PA
Tecfidera	NC, SP, QL (Caps:Daily Dose 2, Starter pack: 1 fill/lifetime)
dimethyl fumarate (generic)	Tier 2; SP, QL (Caps:Daily Dose 2, Starter pack: 1 fill/lifetime)
HUMULIN U-100 HUMALOG U-100 HUMULIN R U-100 HUMULIN N U-100	3 mL insulin vials moved to excluded
Climara patches	NC
emtricitabine-tenofovir disoproxil fumarate (generic)	T2, May be covered at no cost share for HIV PrEP
epoprostenol sodium for inj 0.5 mg and 1.5mg (generic)	MB; PA/SI
Zokinvy (lonafarnib)	Tier 2; PA
Orgovyx (relugolix)	Tier 2; PA
Imcivree (setmelanotide)	Tier 2; PA
Plegridy (peginterferon beta-1a)	Tier 3 SP, QL (2 pens or syringes per 28)
Lifems (naloxone) convenience kit	Excluded
Wynzora (calcipotriene-betamethasone dipropionate) 0.005%-0.064% cream	NC

Cometriq	Added to SP program
Palynziq	Added to SP program
Elelyso	Added to SP/SI program

Key:

- | | |
|--------------------------------|--|
| MB: Medical Benefit | QL: Quantity Limitation |
| NC: Not covered | SP: Specialty Pharmacy - provided through CVS/specialty |
| NTM: New-to-market | ST: Step Therapy |
| PA: Prior Authorization | |